Safety evaluation on low-molecular-weight hydroxyethyl starch for volume expansion therapy in pediatric patients: a meta-analysis of randomized controlled trials by unknown
Li et al. Critical Care  (2015) 19:79 
DOI 10.1186/s13054-015-0815-yRESEARCH Open AccessSafety evaluation on low-molecular-weight
hydroxyethyl starch for volume expansion
therapy in pediatric patients: a meta-analysis of
randomized controlled trials
Lixia Li1†, Yongyang Li2†, Xiaoxing Xu3, Bo Xu4, Rongrong Ren4, Yan Liu1, Jian Zhang1* and Bin He4*Abstract
Introduction: Hydroxyethyl starch (HES) has been widely used for volume expansion, but its safety in adult patients
has been questioned recently. The aim of this meta-analysis is to see whether or not HES has any adverse effect in
pediatric patients.
Methods: Randomized controlled trials (RCTs) involving pediatric patients who received 6% low-molecular-weight HES,
published before January 2014, were searched for in Pubmed, Embase database and Cochrane Library. Two reviewers
independently extracted the valid data, including the mortality, renal function, coagulation, blood loss, hemodynamic
changes, and length of hospital and ICU stay. All data were analyzed by I2-test, and the results of statistical analysis were
displayed in forest plots. Possible publication bias was tested by funnel plots. Bayesian analysis was performed using
WinBUGS with fixed and random effects models.
Results: A total of 13 RCTs involving 1,156 pediatric patients were finally included in this meta-analysis. Compared with
other fluids, HES did not significantly decrease the mortality (RR = -0.01; 95%CI: 0.05 to 0.03; P = 0.54; I2 = 6%), creatinine
level (I2-test: MD = 1.81; 95%CI: -0.35 to 3.98; P = 0.10;I2 = 0%; Bayesian analysis: Fixed effect model MD = 1.77;
95%CI: -0.07 to 3.6; Random effects model MD = 1.78; 95%CI: -1.86 to 5.33), activated partial thromboplastin time
(MD = 0.01; 95%CI: -1.05 to 1.07; P = 0.99; I2 = 42%), and blood loss (MD = 17.72; 95%CI: -41.27 to 5.82; P = 0.10; I2 = 0%)
in pediatric patients. However, HES significantly decreased the blood platelet count (MD = 20.99; 95%CI: -32.08 to -9.90;
P = 0.0002; I2 = 28%) and increased the length of ICU stay (MD = 0.94; 95%CI: 0.18 to 1.70; P = 0.02; I2 = 46%).
Conclusions: Volume expansion with 6% HES significantly decreased the platelet count and increased the length of
ICU stay, also might have an adverse effect on renal function. Therefore HES is not recommended for pediatric patients,
which safety needs more high quality RCTs and studies to confirm in future.Introduction
Hydroxyethyl starch (HES) has been widely used for clinical
volume expansion since the 1960s. However, a series of re-
cent randomized controlled trials (RCTs) [1-3] have ques-
tioned the safety of HES for volume expansion in adult
patients, suggesting that HES may increase the mortality* Correspondence: zj_boss@126.com; hebinicu@139.com
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these studies, the European Society of Intensive Care Medi-
cine (ESICM) recommends that HES should not be used
for volume expansion due to the high risk for inducing kid-
ney injury and bleeding [4]. However, this recommendation
is mainly based on the findings in adult patients. Whether
HES has similar adverse effects in pediatric patients and
whether it can be used safely in children remain un-
answered, knowing that children have different pulmonary,
vascular and cardiac compliances, and different responses
to volume expansion therapy as compared with adult
patients [5-7]. The objective of this meta-analysis was tois an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 The flow chart of the literature search.
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volume expansion in pediatric patients.
Materials and methods
No ethical approval was required because this study in-
cludes no confidential personal data or interventions
on the patients according to the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
[8]. Bayesian analysis on creatinine (Cr) was performed
using WinBUGS (version 1.4.3, MRC Biostatistics Unit,
Cambridge, UK) with fixed and random effects models de-
veloped by Dias [9]. We used 100,000 iterations after an
initial burn-in of 1,000. This meta-analysis included RCTs
for pediatric patients who received 6% low-molecular-
weight HES. The primary parameters were the overall
mortality, renal function, bleeding and coagulation func-
tion. The secondary parameters were hemodynamic pa-
rameters, the amount of fluid used for resuscitation, and
the length of hospital and ICU stay. The inclusion criteria
were: 1) RCTs; 2) patients ≤18 years old; and 3) studies
that included a group of patients receiving 6% low-
molecular-weight (130 kD and 200 kD) HES and a control
group receiving other fluids. RCTs that met one of the fol-
lowing criteria were excluded: 1) no group receiving 6%
low-molecular-weight HES; 2) no valid data available; and
3) studies from Dr. Joachim Boldt.
Search strategies
We searched the PubMed and Embase databases and
the Cochrane Library using the following key words and
related free words: ‘hydroxyethyl starch’, ‘HES’, ‘child’,
‘children’ and ‘pediatric’. The relevant clinical trials were
those published before 19 January 2014 that met the
above criteria. The search was limited to ‘randomized
controlled trials’, ‘human’ and ‘children’, and the language
was restricted to English. The details are shown in
Additional file 1.
Study selection and data extraction
Two reviewers (LL and YL) independently screened the
search results and obtained the full texts according to
the inclusion and exclusion criteria, and independently
extracted the valid data. Data extraction and analysis
were performed under the supervision of an experienced
statistician (XX).
Quality assessment
The literature quality was assessed by the Jadad scoring
system [10]. A study with an overall score ≤2 was con-
sidered poor in quality and >2 was considered high
in quality. We performed risk of bias assessment using
the ‘Risk of bias’ tool in the Cochrane Handbook for
Systematic Reviews of Interventions [11]. We assessed
each study according to the quality domains of randomsequence generation, allocation concealment, blinding of
participants and personnel, incomplete outcome data,
selective outcome reporting and other bias.
Statistical analysis
Data were analyzed by Review Manager (5.2 RevMan,
Cochrane Collaboration). The pooling continuous effect
data were assessed by mean difference (MD). When me-
dian and extreme values were presented in the original
articles, these data were converted into mean and stand-
ard deviation according to relevant formulas [12]. Pool-
ing non-continuous data were assessed by the risk ratio
(RR). If there was more than one group, data were
pooled as one group. Statistical heterogeneity of the data
was analyzed quantitatively by the I2-test [13]. The fixed
effects model was selected if no heterogeneity existed
(I2 < 50%), and the random effects model was selected
in the event of 50% ≤ I2 < 75%. A sensitivity analysis or
subgroup analysis would be performed to exclude the
heterogeneity if I2 ≥ 75%; otherwise only descriptive
analysis would be performed without meta-analysis.
Publication bias was tested by funnel plots. Two-sided
tests were performed with a significant difference at
P <0.05.
Table 1 Characteristics of the included randomized controlled trials
Trial Indication HES group Control group
Program Patients
(n)
Age Weight (kg) Program Patients (n) Age Weight (kg)
Liet et al. 2006 [14] Hypotensive neonates with low cardiac
output and absence of myocardial
dysfunction
6%HES 200/0.5 7 5 ± 6d 1.4 ± 0.7 5% Albumin
Isotonic saline
7 2 ± 1d 1.3 ± 0.6
7 6 ± 10d 0.9 ± 0.3
Standl et al. 2008 [15] Non-cardiac surgery 6%HES 130/0.4 41 8.3 ± 9.2 m 8.0 ± 6.6 5% Albumin 40 8.7 ± 10.9 m 7.1 ± 4.6
Akech et al. 2010 [16] Severe falciparum malaria 6%HES 130/0.4 40 40.3 ± 12.8 m - 6% Dextran 39 40.3 ± 12.8 m -
Van Der Linden et al. 2013 [17] Undergoing elective surgery for
congenital heart disease
6%HES 130/0.4 31 6.1 ± 5.2Y 25.1 ± 24.6 5% Albumin 29 4.8 ± 3.7y 16.7 ± 10.3
Liet et al. 2003 [18] Plasma volume expansion with HES
in the newborn
6% HES 200/0.5 13 3 ± 2.2d 1.27 ± 0.47 5% Albumin 13 5 ± 3d 1.33 ± 0.64
Hanart et al. 2009 [19] Undergoing cardiac surgery with
cardiopulmonary bypass
6%HES 130/0.4 60 23.5 ± 19.8 m 9 ± 4 4% Albumin 59 17.3 ± 20.0 m 8 ± 4.3
Akkucuk et al. 2013 [20] Children undergoing cardiac surgery 6%HES 130/0.4 12 3.9 ± 1.7y 13.5 ± 4.5 Ringer’s acetate 12 5.1 ± 3.7y 16.2 ± 8.8
Chong Sung et al. 2006 [21] Undergoing elective repair of atrial
septal defect, ventricular septal defect
or tetralogy of Fallo
6%HES 130 ⁄0.4 21 31.5 ± 34.6 m 13.7 ± 8.9 Fresh frozen plasma 21 43.5 ± 61.6 m 15.7 ± 13.4
Haas et al. 2007 [22] Prevention of intra-operative
hypovolemia
6% HES 130 ⁄0.4 14 9 ±m 9 ± 2 5% Albumin
4% Gelatine
14 14 ± 9 m 10 ± 2
14 10 ± 10 m 8 ± 3
Wills et al. 2005 [23] Dengue shock syndrome 6%HES 200/0.5 129 9.6 ± 4.9y 26 ± 13.3 5% Dextran
Ringer’s lactate
126 10 ± 4.1y 27 ± 14.5
128 9.8 ± 4.6y 26.8 ± 13.9
Wills et al. 2005 [23] Dengue shock syndrome 6%HES 200/0.5 62 9.3 ± 4.6y 24.8 ± 14.1 5% Dextran 67 8.8 ± 4.6y 25.5 ± 13.4
Sahoo et al. 2007 [24] with CCHD undergoing modified
BT shunt operations
6%HES 200/0.5 25 17.7 ± 12.3 m 7.0 ± 2.4 5% Dextran 25 19.5 ± 14.3 m 7.9 ± 2.4
Osthaus et al. 2009 [25] Aged 0 to 12 years scheduled
for surgery
6%HES 130/0.4 25 4.4 ± 6.4y 18.7 ± 22.2 4% Gelatin 25 4.6 ± 6.3y 20.2 ± 25.0
Witt et al. 2008 [26] Major pediatric surgery 6% HES 25 33.2 ± 40 m 13.4 ± 11 4%Gelatin 25 38.7 ± 39 m 14.2 ± 10
130/0.4
Liet
al.CriticalCare
 (2015) 19:79 
Page
3
of
10
Table 2 Assessment of literature quality
Literature
resources
Randomization Random sequence
generation
Allocation
concealment
Blinding
methodology
Withdrawal
and dropouts
Jadad
score
Liet et al. 2006 [14] Yes Computer-generated Yes Yes 6/0 5
Standl et al. 2008 [15] Yes Sealed randomization envelopes Yes None 13/1 4
Akech et al. 2010 [16] Yes Randomization cards Yes Unclear 16/0 4
Van Der Linden et al. 2013 [17] Yes By means of a macro written in SAS®,
version 9.3.1.
Yes Double-blinded 0/0 5
Liet et al. 2003 [18] Yes Unclear Unclear Double-blinded Unclear 2
Hanart et al. 2009 [19] Yes The randomization assignment was
concealed in an envelope
Yes Double-blinded Unclear 4
Akkucuk et al. 2013 [20] Yes Unclear Unclear Unclear Unclear 1
Chong Sung et al. 2006 [21] Yes Unclear Unclear Unclear Unclear 1
Haas et al. 2007 [22] Yes Unclear Unclear Unclear Unclear 1
Wills et al. 2005 [23] Yes Computer-generated Yes Yes 0/1 5
Sahoo et al. 2007 [24] Yes Unclear Unclear Unclear 0/7 2
Osthaus et al. 2009 [25] Yes Computer-generated Unclear None Unclear 2
Witt et al. 2008 [26] Yes Unclear Unclear None Unclear 1
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Literature search and study selection
Figure 1 is the flow chart of the literature search, which
identified a total of 392 articles, from which 379 were
excluded after reading the titles, abstracts and full texts.
Finally, 13 RCTs were included in this meta-analysis.Characteristics of the articles
The characteristics of the 13 RCTs, involving 1,156 pa-
tients, are shown in Table 1. Four RCTs [14-17] reported
the mortality; five RCTs [14,17-20] reported the effect
on renal function; nine RCTs [15,17-19,21-25] reported
the effects on bleeding and coagulation; seven RCTsTable 3 The assessment risk of bias
Study Sequence
generation
Allocation
concealment
Blinding of p
personnel an
assessors
Liet et al. 2006 [14] Low Low Low
Standl et al. 2008 [15] Low Low Unclear
Akech et al. 2010 [16] Low Low Unclear
Van Der Linden et al. 2013 [17] Low Low Low
Liet et al. 2003 [18] Unclear Unclear Low
Hanart et al. 2009 [19] Low Low Low
Akkucuk et al. 2013 [20] Unclear Unclear Unclear
Chong Sung et al. 2006 [21] Unclear Unclear Unclear
Haas et al. 2007 [22] Unclear Unclear Unclear
Wills et al. 2005 [23] Low Low Low
Sahoo et al. 2007 [24] Unclear Unclear Unclear
Osthaus et al. 2009 [25] Low Unclear Unclear
Witt et al. 2008 [26] Unclear Unclear Low[14-17,19,25,26] reported hemodynamic changes; six RCTs
[15,17,19-21,25] reported the amount of fluid replacement;
four RCTs [15,17,19,20] reported the length of ICU stay;
and four RCTs [15,19,20,23] reported the total length of
hospital stay.Quality of the included studies
As shown in Table 2, the study quality was assessed using
the Jadad scoring system. Seven RCTs were of low quality
(≤2) and six RCTs were of high quality (>2). More details
about the risk of bias assessment are shown in Table 3.
The overall risk of bias in four RCTs was low, and that in
the other RCTs was unclear.articipants,
d outcome
Incomplete
outcome data
Selective outcome
reporting
Other
bias
Overall risk
of bias
Low Low Low Low
Low Low Low Unclear
Low Low Low Unclear
Low Low Low Low
Low Low Low Unclear
Low Low Low Low
Low Low Low Unclear
Low Low Low Unclear
Low Low Low Unclear
Low Low Low Low
Low Low Low Unclear
Low Low Low Unclear
Low Low Low Unclear
Figure 2 The forest plot of pooled risk ratio for overall mortality. CI, confidence interval; HES, hydroxyethyl starch; M-H, Mantel-Haenszel.
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In total, four RCTs reported the overall mortality in 310
pediatric patients, including four deaths in 150 children
of the HES group and eight deaths in 160 children of
the other fluid groups. There was no significant differ-
ence in mortality between the HES group and the other
fluid groups (RR = -0.01; 95%CI: -0.05 to 0.03; P = 0.54;
I2 = 6%) (Figure 2). Funnel plots showed no publication
bias (Additional file 2: Figure S1).
Renal function
Three RCTs reported Cr change in 205 pediatric patients,
including 104 in the HES group and 101 in the control
group. The results of statistical analysis showed no signifi-
cant difference in Cr between the HES group and the
other fluid groups (MD= 1.81; 95%CI: -0.35 to 3.98;
P = 0.10; I2 = 0%) (Figure 3). Funnel plots showed no
publication bias (Additional file 3: Figure S2). Bayesian
analysis was performed on Cr using the fixed and random
effects models developed by Dias et al. [9]. The results
showed no significant difference between the two groups
(fixed effect model MD= 1.77; 95%CI: -0.07 to 3.6;
random effects model MD= 1.78; 95%CI: -1.86 to 5.33)
(Figure 4).
Bleeding and coagulation function
Seven RCTs reported changes in coagulation function
within 24 hours, including 521 pediatric patients (228 in
the HES group and 293 in the other fluid groups). We
performed subgroup analysis on surgery (five RCTs
using 130 kD HES) and non-surgery (two RCTs using
200 kD HES), or different molecular-weight HES. The
result showed no significant difference in activatedFigure 3 Forest plot of pooled risk ratio for the effect on renal functi
starch; IV, inverse variance.partial thromboplastin time (APTT) between the
HES group and the other fluid groups (MD = 0.01; 95%
CI: -1.05 to 1.07; P = 0.99; I2 = 42%) (Figure 5a). There
was a significant difference in postoperative platelet
count (MD = -20.99; 95%CI: -32.08 to -9.90; P = 0.0002;
I2 = 28%) (Figure 5b). Four RCTs reported blood loss
on the first day post-operation. The result of statistical
analysis showed no significant difference in blood loss
between the HES group and the other fluid groups
(MD = -9.12; 95%CI: -31.06 to 12.82; P = 0.42; I2 = 52%)
(Figure 5c). Funnel plots showed no publication bias
(Additional file 4: Figure S3a, b, c).
Hemodynamics
Four RCTs reported changes in mean arterial pressure
(MAP) and heart rate (HR) on the first day post-
operation. The results of statistical analysis showed no
significant difference in MAP and HR between the HES
group and the other fluid groups (MAP: MD = -0.99;
95%CI: -3.22 to 1.25; P = 0.39; I2 = 0%; HR: MD = 2.37;
95%CI:-0.39 to 5.12; P = 0.09; I2 = 0%) (Figure 6a, b).
Funnel plots showed no publication bias. Three RCTs
reported the amount of fluid replacement on the first
day post-operation. There was significant heterogeneity
within 24 hours of surgery (I2 = 71%). Given multiple
factors that may affect the amount of fluid replacement,
we only did descriptive analysis without meta-analysis.
Length of hospital and ICU stay
Four RCTs reported the length of hospital stay. The
results showed no significant difference in the length of
hospital stay between the HES group and the other
groups (MD= 0.02; 95%CI: -0.28 to 0.31; P = 0.91; I2 = 0%)on (I2-test). CI, confidence interval; Cr, creatinine; HES, hydroxyethyl
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longer than that in the other groups (MD= 0.94; 95%CI:
0.18 to1.70; P = 0.02; I2 = 46%) (Figure 7b). Funnel plots
showed no publication bias.
Discussion
The results of this meta-analysis showed that HES sig-
nificantly decreased the platelet count and increased
the length of ICU stay, and also might have had an ad-
verse effect on renal function. Therefore, it should not
be recommended for use in pediatric patients before its
safe use in children is confirmed by more high-quality
RCTs.
HES might have effects on the mortality of pediatric pa-
tients. However, this meta-analysis did not show that HES
significantly decreased the mortality of pediatric patients
as compared with other fluids, which is consistent with
the conclusion made by previous studies in pediatric pa-
tients [16,23,27-29]. More findings suggest that HES might
have adverse effects on the mortality of adult patients.
Sedrakyan et al. [30] reported that the use of HES was
linked with a poorer survival as compared with albumin.
Trowbridge et al. [31] also reported that elimination of
HES was associated with a 67% decrease in the relative
odds of death in patients undergoing cardiopulmonary by-
pass surgery. There still needs more high quality RCTsTraditional meta−analysis
Bayesian (fixed model)
Bayesian (random model)
ID
Study
−5.33
Figure 4 Forest plot of pooled risk ratio for the effect on renal functi
developed by Dias [9]). CI, confidence interval; Cr, creatinine; HES, hydroxand studies to confirm the effect of HES on mortality of
pediatric patients in future.
This meta-analysis showed HES might have an adverse
effect on renal function, which trend was much stronger.
Most studies in adult patients also showed that HES had
an adverse effect on renal function. This meta-analysis
showed that HES did not decrease the Cr level in
pediatric patients as compared with other fluids. Consid-
ering the wide confidence intervals of the result on Cr
and small sample size in the meta-analysis, we cannot
conclude that HES is safe in pediatric patients. We used
Bayesian analysis to test the possible significant differ-
ence. Although compared with previous meta-analysis,
Bayesian analysis of the fixed model indicated that the
trend was much stronger; the results also showed that
there was no significant difference between the two
groups. Knowing that many studies reported an associ-
ation of HES use with an increased incidence of acute
kidney injury in adult patients [32-34], it is not unwise
to suggest that HES might have adverse effects on renal
function and should not be used in pediatric patients
with abnormal renal function.
This meta-analysis showed that HES significantly de-
creased the blood platelet count and might have an ad-
verse effect on the coagulation system in pediatric
patients as compared with other fluids, although it did1.81 (−0.35, 3.98)
1.77 (−0.07, 3.60
1.78 (−1.86, 5.33
MD (95% CI)
)
)
0 5.33
on (Bayesian analysis with fixed and random effects models
yethyl starch.
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tients. Most studies [15,21,25,35] reported that there
was no significant change in prothrombin time (PT) and
APTT after HES administration in pediatric patients.
However, Haas et al. [22] reported that HES prolonged
APTT and the blood clotting time and significantly in-
creased the hardness of blood clots. Miller BE et al. [36]
also reported that the increased blood loss after cardio-
pulmonary bypass in pediatric patients may be associ-
ated with the use of HES. Coagulation dysfunction is a
common cause of excessive bleeding during and after
cardiac surgery. Coagulation dysfunction occurring after
cardiopulmonary bypass may be partly caused by platelet
loss [37,38]. Thus, platelet loss is a very importantStudy or Subgroup
Chong Sung 2006
Haas 2007
Hanart 2009
Standl 2008
Van Der Linden 2013
Total (95% CI)
Heterogeneity: Chi² = 5.56, df = 4 (P = 0.23); I² = 28%
Test for overall effect: Z = 3.71 (P = 0.0002)
Mean
140.7
195.3
167
313
177.3
SD
49.6
40.8
47.1
107.5
76.6
Total
21
14
60
41
31
167
Mean
137.2
233.9
187.5
347.5
214.2
SD
38
46
35
110.8
108.6
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21
28
59
40
29
177
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17
16
55
5
5
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a
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Chong Sung 2006
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Test for overall effect: Z = 0.81 (P = 0.42)
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135.6
479.7
69.3
34.7
SD
65.8
180
56
84
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21
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25
41
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136.6
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46.5
SD
61.2
156
93.2
105.7
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21
59
25
40
145
Wei
32.
13.
26.
27.
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Experimental Control
b
c
Study or Subgroup
APTT on the first day Post-operation(130/0.4)
Chong Sung 2006
Haas 2007
Hanart 2009
Standl 2008
Van Der Linden 2013
Subtotal (95% CI)
Heterogeneity: Chi² = 9.09, df = 4 (P = 0.06); I² = 56%
Test for overall effect: Z = 0.31 (P = 0.76)
 APTT on the first day non-surgery(200/0.5)
Liet 2003
Wills 2005
Wills2005
Subtotal (95% CI)
Heterogeneity: Chi² = 0.38, df = 2 (P = 0.83); I² = 0%
Test for overall effect: Z = 1.60 (P = 0.11)
Total (95% CI)
Heterogeneity: Chi² = 12.12, df = 7 (P = 0.10); I² = 42%
Test for overall effect: Z = 0.01 (P = 0.99)
Test for subgroup differences: Chi² = 2.65, df = 1 (P = 0.10), I² = 62.2%
Mean
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36.3
37.1
38.73
47
47.9
53.3
SD
15.5
4.1
4.8
6.5
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22.3
22
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14
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31
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13
36
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39.6
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7
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13
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125
293
We
0
9
63
11
10
9
1
1
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Figure 5 Forest plots of pooled estimates for the effect on coagulatio
b) Platelet count. c) Blood loss. CI, confidence interval; HES, hydroxyethyl stadverse effect on heart surgery. These hemostatic con-
cerns about HES have been further substantiated by a
meta-analysis of children and adults receiving HES dur-
ing cardiac surgery, which showed increased blood loss
in the patients receiving HES compared with albumin
[39]. The present study showed that HES might have
an unfavorable effect on the coagulation system in
pediatric patients, especially those who underwent heart
surgery.
This meta-analysis showed that HES significantly
increased the length of ICU stay. Many studies [40-42]
reported the same result on the length of hospital stay
between the HES group and other solution groups, but
we found no related report on the length of ICU stay inight
.2%
.5%
.5%
.4%
.4%
.0%
IV, Fixed, 95% CI
3.50 [-23.22, 30.22]
-38.60 [-65.93, -11.27]
-20.50 [-35.39, -5.61]
-34.50 [-82.06, 13.06]
-36.90 [-84.75, 10.95]
-20.99 [-32.08, -9.90]
Mean Difference Mean Difference
IV, Fixed, 95% CI
-100 -50 0 50 100
HES control group
ght
6%
2%
5%
8%
.0%
IV, Fixed, 95% CI
-1.00 [-39.43, 37.43]
47.70 [-12.79, 108.19]
-44.50 [-87.12, -1.88]
-11.80 [-53.44, 29.84]
-9.12 [-31.06, 12.82]
Mean Difference Mean Difference
IV, Fixed, 95% CI
-100 -50 0 50 100
HES control group
ight
.9%
.9%
.7%
.3%
.3%
6.2%
.3%
.9%
.7%
3.8%
.0%
IV, Fixed, 95% CI
11.50 [0.58, 22.42]
2.00 [-1.37, 5.37]
0.00 [-1.33, 1.33]
-2.50 [-5.65, 0.65]
-1.81 [-5.11, 1.49]
-0.17 [-1.25, 0.91]
2.00 [-7.42, 11.42]
5.40 [-2.38, 13.18]
6.10 [-6.43, 18.63]
4.41 [-1.00, 9.82]
0.01 [-1.05, 1.07]
Mean Difference Mean Difference
IV, Fixed, 95% CI
-20 -10 0 10 20
HES Control
n and bleeding. a) activated partial thromboplastin time (APTT).
arch; IV, inverse variance.
ab
Figure 6 Forest plots of pooled estimates for the effect on hemodynamics. a) mean arterial pressure (MAP). b) heart rate (HR). CI,
confidence interval; HES, hydroxyethyl starch; IV, inverse variance.
Li et al. Critical Care  (2015) 19:79 Page 8 of 10adult patients. Given the limited number of studies
enrolled in this meta-analysis, more clinical studies with
larger sample sizes are needed to confirm the association
between HES use and the length of ICU stay.
There are several limitations in this meta-analysis.
First, the analysis is based on only 13 RCTs and some of
them had a relatively small sample size of pediatric pa-
tients. Second, the control groups in these studies usedStudy or Subgroup
Akkucuk 2013
Hanart 2009
Standl 2008
Van Der Linden 2013
Total (95% CI)
Heterogeneity: Chi² = 5.52, df = 3 (P = 0.14); I² = 46%
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3
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Figure 7 Forest plots of pooled estimates for the effect on the length
length of ICU stay. CI, confidence interval; HES, hydroxyethyl starch; IV, invemultiple different fluids including fresh frozen plasma,
dextran, albumin, gelatin and crystalloids, and, therefore,
it is difficult to make a subgroup analysis according to
the different fluids. Finally, although there is no hetero-
geneity between the included studies, patient character-
istics including age of the enrolled children and other
baseline data are different, which may affect the accuracy
of the meta-analysis results.ight
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Li et al. Critical Care  (2015) 19:79 Page 9 of 10Conclusions
Volume expansion with 6% HES significantly decreased
the platelet count and increased the length of ICU stay,
and also might have an adverse effect on renal function.
Therefore, HES is not recommended for use in
pediatric patients before more studies confirm these
results.
Key messages
 HES decreased the platelet count and increased the
length of ICU stay in pediatric patients, and might
have adverse effects on coagulation function.
 HES might have an adverse effect on renal function.
 HES is not recommended for use in pediatric
patients before more studies confirm these results.
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